A Fallen Giant Pfizer (NYSE:PFE) has been a bitter pill for investors to swallow. Down 19% from its 52-week high of $30.43 per share, PFE stock has plummeted over 50% in the past three years, a stark ...

At first glance, Pfizer delivered a strong Q2 and upped its 2025 full-year EPS guidance. Click here to find out why I rate PFE stock a Sell.

Realty Income is a real estate investment trust that has raised its dividend payout 131 times since 1994. Verizon's a ...

Pfizer is a solid dividend stock. Its forward yield currently tops 7%, and the company has increased its payouts by 19.5% in ...

Pfizer Inc. (NYSE:PFE) discovers, develops, markets, and sells biopharmaceutical products in the U.S. and internationally. It ...

These three dividend stocks are trading on the cheap given their true valuations. They should be on income investors' radars.

Those who invested in Pfizer three years ago and hung on are not thrilled. They would have done much better with a simple S&P ...

Pfizer's diversified pipeline and new product launches are driving operational growth. Click here to read more about PFE ...

One of the highest yields you can get right now is from Pfizer (NYSE: PFE). The healthcare giant offers a yield of 6.8%, ...

Looking ahead, Pfizer Inc. (NYSE:PFE) plans to achieve $7.2 billion in cost savings by 2027, which should improve cash flow and provide more flexibility for sustaining its dividend.

Three Motley Fool contributors think they've found unstoppable dividend stocks to buy right now. Here's why they picked ...